リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

Maeda, Osamu Ohka, Fumiharu Maesawa, Satoshi Matsuoka, Ayumu Shimokata, Tomoya Mitsuma, Ayako Urakawa, Hiroshi Nakamura, Shota Shimoyama, Yoshie Nakaguro, Masato Wakabayashi, Toshihiko Ando, Yuichi 名古屋大学

2020.11

概要

Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare tumor derived from mesenchymal tissue. Although standard chemotherapy for SHT/HPC has not been established, temozolomide plus bevacizumab (TMZ+Bev) therapy for SFT/HPC has been reported. The effectiveness and safety of TMZ+Bev (temo-zolomide 150 mg/m2 orally on days 1–7 and days 15–21 and bevacizumab 5 mg/kg intravenously on day 8 and day 22 on a 28-day cycle), which was administered from December 2013 until April 2019 to four patients with SFT/HPC, were retrospectively analyzed. Four patients with SFT/HPC received TMZ+Bev. The age of the patients ranged from 41 to 75 years. Two were male, and the primary tumor sites were the meninges in three patients and the pleura in one. One achieved partial response; the others, stable disease (SD). The progression-free survival time ranged from 9.4 to 29.6 months according to RECIST v1.1. One patient died 59 months after using TMZ+Bev, and the others survived for 17 to 64 months. All patients experienced Grade 3 or higher lymphopenia, and three had Grade 3 or higher leukopenia and neutropenia. One patient subsequently received doxorubicin; another, pazopanib. TMZ+Bev therapy for SFT/HPC is safe and effective for maintaining long-term SD.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Vallat-Decouvelaere AV, Dry SM, Fletcher CD. Atypical and malignant solitary fibrous tumors in

extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol.

1998;22(12):1501–1511.

2. Metellus P, Bouvier C, Guyotat J, et al. Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery. 2007;60(4):715–722; discussion 722.

DOI: 10.1227/01.NEU.0000255418.93678.AD

3. Chamberlain MH, Taggart DP. Solitary fibrous tumor associated with hypoglycemia: an example of the

Doege-Potter syndrome. J Thorac Cardiovasc Surg. 2000;119(1):185–187.

4. Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P. Solitary fibrous tumor

of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report. J Thorac Oncol.

2006;1(6):588–590.

5. de Groot JW, Rikhof B, van Doorn J, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the

literature including two new cases. Endocr Relat Cancer. 2007;14(4):979–993. DOI: 10.1677/ERC-07-0161

6. Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical

review. J Clin Endocrinol Metab. 2014;99(3):713–722. DOI: 10.1210/jc.2013-3382

7. Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal antibody

is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology.

2014;46(5):389–395. DOI: 10.1097/PAT.0000000000000122

8. Franzen D, Diebold M, Soltermann A, et al. Determinants of outcome of solitary fibrous tumors of the

pleura: an observational cohort study. BMC Pulm Med. 2014;14:138. DOI: 10.1186/1471-2466-14-138

9. Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification

of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763–1774. DOI: 10.1002/cncr.28657

10. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors

of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820. DOI: 10.1007/s00401016-1545-1

11. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6

644

Osamu Maeda et al

fusion in solitary fibrous tumors. Nat Genet. 2013;45(2):131–132. DOI: 10.1038/ng.2522

12. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions

in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45(2):180–185. DOI: 10.1038/ng.2509

13. Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/

STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile

in solitary fibrous tumor. Genes Chromosomes Cancer. 2013;52(10):873–886. DOI: 10.1002/gcc.22083

14. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry

the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol.

2013;125(5):651–658. DOI: 10.1007/s00401-013-1117-6

15. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes

solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27(3):390–395. DOI: 10.1038/modpathol.2013.164

16. Fritchie KJ, Jin L, Rubin BP, et al. NAB2-STAT6 Gene Fusion in Meningeal Hemangiopericytoma and

Solitary Fibrous Tumor. J Neuropathol Exp Neurol. 2016;75(3):263–271. DOI: 10.1093/jnen/nlv026

17. Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer.

2011;117(21):4939–4947. DOI: 10.1002/cncr.26098

18. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission

tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with

imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–

1759. DOI: 10.1200/JCO.2006.07.3049

19. Constantinidou A, Jones RL, Olmos D, et al. Conventional anthracycline-based chemotherapy has limited

efficacy in solitary fibrous tumour. Acta Oncol. 2012;51(4):550–554. DOI: 10.3109/0284186X.2011.626450

20. Park MS, Ravi V, Conley A, et al. The role of chemotherapy in advanced solitary fibrous tumors: a

retrospective analysis. Clin Sarcoma Res. 2013;3(1):7. DOI: 10.1186/2045-3329-3-7

21. Stacchiotti S, Libertini M, Negri T, et al. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013;49(10):2376–2383. DOI: 10.1016/j.ejca.2013.03.017

22. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the

treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–263. DOI:

10.1093/annonc/mds237

23. Stacchiotti S, Tortoreto M, Bozzi F, et al. Dacarbazine in solitary fibrous tumor: a case series analysis and

preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res. 2013;19(18):5192–5201.

DOI: 10.1158/1078-0432.CCR-13-0776

24. Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue

sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–1052.

DOI: 10.1016/S1470-2045(11)70230-3

25. Khalifa J, Ouali M, Chaltiel L, et al. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer. 2015;15:700. DOI: 10.1186/s12885-015-1697-8

26. Maruzzo M, Martin-Liberal J, Messiou C, et al. Pazopanib as first line treatment for solitary fibrous tumours:

the Royal Marsden Hospital experience. Clin Sarcoma Res. 2015;5:5. DOI: 10.1186/s13569-015-0022-2

27. Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al. Pazopanib for treatment of advanced malignant

and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol.

2019;20(1):134–144. DOI: 10.1016/S1470-2045(18)30676-4

28. Valentin T, Fournier C, Penel N, et al. Sorafenib in patients with progressive malignant solitary fibrous

tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New

Drugs. 2013;31(6):1626–1627. DOI: 10.1007/s10637-013-0023-z

29. Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol.

2012;23(12):3171–3179. DOI: 10.1093/annonc/mds143

30. Stacchiotti S, Simeone N, Lo Vullo S, et al. Activity of axitinib in progressive advanced solitary

fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. Eur J Cancer.

2019;106:225–233. DOI: 10.1016/j.ejca.2018.10.024

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る